1442469-17-1

Basic information

• Product Name: N-[4-(2-phenylethyl)-1H-imidazol-2-yl]acetamide
• Synonyms: N-[4-(2-phenylethyl)-1H-imidazol-2-yl]acetamide
• CAS NO: 1442469-17-1
• Molecular Weight: 229.282
• Mol File: 1442469-17-1.mol

Chemical Properties

• CAS DataBase Reference: N-[4-(2-phenylethyl)-1H-imidazol-2-yl]acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-[4-(2-phenylethyl)-1H-imidazol-2-yl]acetamide(1442469-17-1)
• EPA Substance Registry System: N-[4-(2-phenylethyl)-1H-imidazol-2-yl]acetamide(1442469-17-1)

Safety Data

• Hazardous Substances Data: 1442469-17-1(Hazardous Substances Data)

Upstream product

• 5699-40-1 acetylguanidine 
• 31984-10-8 1-bromo-4-phenylbutan-2-one 
• 2550-26-7 4-Phenyl-2-butanone 

Downstream Products

• 1033822-52-4 4-(2-phenylethyl)-1H-imidazol-2-amine 

Relevant articles and documents

Novel 1H-imidazol-2-amine derivatives as potent and orally active vascular adhesion protein-1 (VAP-1) inhibitors for diabetic macular edema treatment

Novel thiazole derivatives were synthesized and evaluated as vascular adhesion protein-1 (VAP-1) inhibitors. Although we previously identified a compound (2) with potent VAP-1 inhibitory activity in rats, the human activity was relatively weak. Here, to improve the human VAP-1 inhibitory activity of compound 2, we first evaluated the structure-activity relationships of guanidine bioisosteres as simple small molecules and identified a 1H-benzimidazol-2-amine (5) with potent activity compared to phenylguanidine (1). Based on the structure of compound 5, we synthesized a highly potent VAP-1 inhibitor (37b; human IC50 = 0.019 μM, rat IC50 = 0.0051 μM). Orally administered compound 37b also markedly inhibited ocular permeability in streptozotocin-induced diabetic rats after oral administration, suggesting it is a promising compound for the treatment of diabetic macular edema.